AstraZeneca's Farxiga clears late-stage heart-failure study

British drugmaker AstraZeneca Plc said on Tuesday that its diabetes drug Farxiga was successful in reducing the risk of death by heart attack or the worsening of a type of heart failure in a late-stage study.